Domestic News - Huawei announced the open-source release of its Cangjie programming language on July 30, aimed at full-scene application development and supporting operating systems like Euler and Harmony [2] - Yushu Technology completed a C round financing of approximately 700 million RMB, achieving a post-financing valuation of about 12 billion RMB, and is actively pursuing an IPO, primarily targeting the A-share market [3][32] - Huawei launched its new generation Ascend AI cloud service based on the CloudMatrix384 super node, which integrates 384 Ascend NPUs and 192 Kunpeng CPUs, achieving a single-card inference throughput of 2300 Tokens/s [4] - Dingjie Smart released the "2025 Generative AI Enterprise Application Practical Report," analyzing ten major applications of generative AI in enterprises [5] - Ant Group established a new technology company in Hangzhou with a registered capital of 30 million RMB, focusing on software development and data processing services [6] - Huawei introduced the CloudRobo embodied intelligence platform, which integrates various capabilities for data synthesis, model development, and cloud-edge collaboration [7] - Yuxin Technology submitted its listing application to the Hong Kong Stock Exchange [8] - Zhongke Xingtou resumed participation in military material engineering service procurement activities after a suspension [9] - RIK Chemical plans to establish a joint venture for intelligent computing technology with a registered capital of 40 million RMB [10] - Juchip Technology announced the successful promotion of its new AI audio chips, achieving significant market traction [11] - The first two data center REITs in China have been approved, marking a significant expansion in the public REITs market [12] International News - Microsoft plans to lay off thousands of employees, primarily in the sales department, with the announcement expected after the end of the fiscal year [22] - OpenAI is offering discounts on its ChatGPT enterprise version, with expected annual revenue from enterprise clients nearing $15 billion by 2030 [23] - Intel appointed new executives to enhance its sales and engineering leadership [24] - South Korea plans to invest 16.1 trillion KRW in artificial intelligence over the next five years [27] - Elon Musk's AI company xAI's acquisition of X is under investigation by the EU, with potential fines expected [29] - Medical technology company Semler Scientific appointed a Bitcoin strategy director, planning to hold 105,000 Bitcoins by the end of 2027 [30] - TerraPower, founded by Bill Gates, completed a $650 million financing round with participation from Nvidia's venture capital arm [31] Policy & Trends - Over 300 cities in China have achieved 5G-A coverage, with more than 10 million users [38] - The Ministry of Education in China emphasized the need to enhance population quality in the western regions through education [39] - The National Internet Information Office reported that 433 large models have been registered in China [40] - China Mobile's chairman stated that silicon-based life forms will surpass humans in number, creating a new "population dividend" [41] - Huawei's chairman noted that the telecom market is entering a phase of demand fragmentation and technological iteration [42] - The China Securities Regulatory Commission announced support for more frontier technology companies to apply for the Sci-Tech Innovation Board [43] - Wuhan introduced measures to support talent development in the AI sector [44] - The Central Cyberspace Administration of China launched a campaign to address the misuse of AI technology, achieving significant progress in the first phase [45]

Monetization is the permanent increase in the monetary base to fund the government. Central banks buy interest-bearing debt with non-interest-bearing money. https://t.co/8CKfWw7Wmm ...

Core Insights - CureVac N.V. (CVAC) shares have increased by 40.8% in one month following a definitive acquisition agreement by BioNTech SE (BNTX) valued at approximately $1.25 billion [1][5] - Each CVAC share will be exchanged for about $5.46 worth of BNTX American Depositary Shares (ADS), representing a 55% premium over CVAC's three-month volume-weighted average price of $3.53 [2][5] - The transaction is expected to close in 2025, pending customary closing conditions and regulatory approvals [2] Company Benefits - The acquisition will enhance BioNTech's capabilities in mRNA-based cancer immunotherapies by expanding its research, development, manufacturing, and commercialization infrastructure [6] - This deal allows BioNTech to broaden its oncology pipeline and focus on newer programs across various tumor types, including mRNA-based cancer candidates and BNT327, a bispecific antibody [7] - BioNTech's existing strengths in mRNA design and delivery technologies will be complemented by CureVac's assets, further solidifying its position in the market [6] Strategic Collaborations - Earlier in June, BioNTech entered a strategic collaboration with Bristol Myers (BMY) for the co-development and co-commercialization of BNTX's BNT327, with an upfront payment of $1.5 billion and potential additional payments totaling $2 billion through 2028 [8] - BNT327 is currently in late-stage clinical studies for lung cancer and is set to enter a phase III study for triple-negative breast cancer by the end of 2025 [8]

Core Insights - Capricor Therapeutics announced positive four-year safety and efficacy results for Deramiocel, its lead cell therapy candidate for Duchenne Muscular Dystrophy (DMD) [1][3] - The findings will be presented at the PPMD 2025 Annual Conference, highlighting the importance of addressing both cardiac and skeletal muscle functions in DMD treatment [1][4] Efficacy Results - After four years of treatment, Deramiocel-treated patients showed a median change of -0.5 points compared to baseline, indicating clinical benefit, especially in patients with baseline LVEF >45% [2] - The treatment also slowed skeletal muscle disease progression, with a smaller average decline in Performance of the Upper Limb (PUL v2.0) in the fourth year (0.6 points) compared to the first year (1.8 points) [3][7] Safety Profile - Deramiocel maintained a favorable safety profile throughout the study, reinforcing its potential as a therapeutic option for DMD [3][7] Regulatory Progress - Capricor is in the process of obtaining regulatory approval for Deramiocel, with its Biologics License Application (BLA) under priority review and no evidence of delays in discussions with the FDA [4][10] Study Background - The HOPE-2 study was a randomized, double-blind, placebo-controlled Phase 2 trial, with patients receiving intravenous infusions of Deramiocel (150 million cells) every three months [5] - Following the study, all patients entered a treatment gap phase before enrolling in the HOPE-2 Open-Label Extension (OLE) study, which continues to monitor safety and efficacy [5] About Duchenne Muscular Dystrophy - DMD is a severe genetic disorder affecting approximately 15,000 individuals in the U.S., characterized by progressive muscle degeneration and leading to cardiomyopathy, which is a major cause of mortality [6][9] About Deramiocel - Deramiocel (CAP-1002) consists of allogeneic cardiosphere-derived cells (CDCs) known for their immunomodulatory and anti-fibrotic properties, which may help preserve cardiac and skeletal muscle function in DMD [8][10] - The therapy has received multiple designations from regulatory agencies, including Orphan Drug Designation and Regenerative Medicine Advanced Therapy (RMAT) designation [9]

Hello, and welcome to the presentation on Independent Control of AI Engine Partitions. In this Tech module, we’ll start with an introduction to AI Engine independent partitioning. Next, we’ll cover the AI Engine kernel workflow, detailing the process of compilation, linking, and packaging.We’ll then dive into modular control over partition management and reloading, discussing the flexibility it offers for efficient development. After that, we’ll go through key system considerations, highlighting what’s avai ...

HealthStream。 1Q 2025 Investor Presentation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ©2025 HealthStream HealthStream. Safe Harbor Statement This presentation includes certain forward-looking statements (statements other than solely with respect to historical fact), including statements regarding expectations for the financial performance for 2025 that involve risks and uncertainties regarding HealthStream. These statements are based upon management's beliefs, as we ...

Investor Day & Longevity Summit June 12, 2025 abacusgm.com Disclaimer General. This presentation (this "Presentation") is provided solely for informational purposes. This Presentation is subject to update, completion, revision, verification and further amendment without notice. None of Abacus Global Management, Inc. (the "Company", "Abacus", Abacus Global Management", "we", "our", or "us") or its affiliates has authorized anyone to provide interested parties with additional or different information. The inf ...

Lavoro Limited (LVRO) Q2 2025 Earnings Call June 18, 2025 05:00 PM ET Speaker0 Welcome to Lovallo's Business Update Conference Call. Please note that this conference call is being recorded and a replay will be made available on the company's Investor Relations website at ir.lavoroagro.com. I will now turn the conference over to Tigran Karpishin, Head of Investor Relations. Thank you. You may begin. Speaker1 Thank you for joining us today to discuss our business update. We will be covering the out of court r ...

SAXONBURG, Pa., June 18, 2025 (GLOBE NEWSWIRE) -- Coherent Corp. (NYSE: COHR), a global leader in photonics, today announced the launch of its new line of disposable surgical fiber assemblies designed specifically for a wide range of precision medical applications. The new product line is suitable for both OEM integration and for direct clinical use. Engineered to meet the rigorous demands of modern surgical environments, the new fiber assemblies deliver exceptional optical performance, robust durability, a ...

[Music] On June 13th, the Environmental Protection Agency released its long-awaited renewable volume obligation proposal for 2026 and 2027 under the renewable fuel standard. The proposal will greatly increase the required volume of biomassbased diesel blended by refiners from 3.35% billion gallons in 2025 to 5.61% 61 billion gallons in 2026 and 2027. The proposal also prioritizes using soybean oil and ethanol produced in the United States and discourages the use of biomass and feed stocks produced outside o ...